A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safetytolerability and preliminary efficacy of B019 in subjects with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.